167 results
Page 6 of 9
8-K
EX-99.1
2hg3f6
3 Jun 20
Replimune Reports Fiscal Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
7:26am
8-K
EX-99.2
pa3sw kiy
3 Jun 20
Regulation FD Disclosure
7:25am
8-K
EX-10.1
o7l mhoe8
9 Dec 19
Departure of Directors or Certain Officers
5:02pm
8-K
EX-1.1
l5a9 ghrof
18 Nov 19
Replimune Announces Proposed Public Offering
8:02am
8-K
EX-4.1
nmwyddbvj 3qju
18 Nov 19
Replimune Announces Proposed Public Offering
8:02am
424B5
uqxmtal54jgruw
18 Nov 19
Prospectus supplement for primary offering
7:40am
424B5
gs1ojt qct83
12 Nov 19
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
m81oocsx1ejqm6
15 Oct 19
Replimune Provides Update on RP1 Clinical Development Program in Cutaneous Squamous Cell Carcinoma
8:24am
UPLOAD
qf2yka ttc
12 Aug 19
Letter from SEC
12:00am
DEF 14A
b4dgze
9 Aug 19
Definitive proxy
4:05pm
8-K
EX-10.2
g4iccdy
8 Aug 19
Entry into a Material Definitive Agreement
5:14pm
S-3
m75wcenm0n95zi9 cv9
8 Aug 19
Shelf registration
5:05pm
S-3
EX-1.2
s6w7ld vv
8 Aug 19
Shelf registration
5:05pm